Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

Overview of attention for article published in Arthritis Research & Therapy, December 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 2 news outlets

twitter: 16 X users

Citations

dimensions_citation: 193 Dimensions

Readers on

mendeley: 176 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

Infection Risks Similar for Xeljanz, Biologics in RA

MedPage Today, 28 Dec 2015

Action Points In patients with rheumatoid arthritis, the risks of serious infections were similar for tofacitinib and various…

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

Bioportfolio, 15 Dec 2015

Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.